Novel Purification of Advanced Biopharmaceutical Antibodies, Antibody Derivatives and Recombinant Proteins

Purius是一家初创企业，开发一种新的生物制药药物纯化系统，我们称之为“无树脂纯化”。在竞争日益激烈的生物制品制造领域，复杂的纯化过程往往是商品成本中最昂贵的部分。我们的目标是通过消除所有传统的处理步骤来消除这种复杂性，将它们浓缩成一个简化的、可持续的、从根本上更便宜的操作。我们的创新技术有可能改变目前的生物制造业务。该项目旨在扩展我们之前在抗体纯化方面的工作，扩大我们纯化技术的潜在目标，同时迅速提高我们的实验能力。我们的团队由一群在该领域拥有多年工业和学术经验的专家组成，我们相信我们已经制定了一个商业计划，可以在最短的时间内以最低的风险迅速将这项技术推向市场。这笔拨款可以帮助我们实现这一目标，帮助药品制造商，并最终帮助患者。

Purius is a startup business developing a novel system for the purification of biopharmaceutical drugs that we call "resin-free purification". In the increasingly competitive field of biologics manufacture, the complex purification process is often the most expensive contributor to cost of goods. We aim to eliminate that complexity by eliminating all the traditional processing steps, condensing them into one simplified, sustainable and radically cheaper operation. Our innovative technology has the potential to transform current biomanufacturing operations.This project looks to expand on our previous work on antibody purification, expanding the potential targets for our purification technology whilst rapidly increasing our experimental capabilities.Our team comprises of a group of experts in the field with years of industrial and academic experience with a track record of innovation in the field, and we believe we have developed a business plan that can rapidly move this technology to market at the lowest risk and in the shortest time possible. The grant funding can help us reach that goal, to help drug manufacturers, and ultimately, help patients.